AbbVie Inc.

BUL:4AB Stock Report

Market Cap: €299.3b

AbbVie Past Earnings Performance

Past criteria checks 1/6

AbbVie has been growing earnings at an average annual rate of 1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9.3% per year. AbbVie's return on equity is 84.5%, and it has net margins of 9.1%.

Key information

1.0%

Earnings growth rate

-2.1%

EPS growth rate

Biotechs Industry Growth14.2%
Revenue growth rate9.3%
Return on equity84.5%
Net Margin9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AbbVie makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BUL:4AB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2455,5335,08113,8657,755
30 Jun 2455,0005,29813,1347,405
31 Mar 2454,4035,95112,9737,189
31 Dec 2354,3184,82012,9047,038
30 Sep 2355,1386,47112,4536,897
30 Jun 2356,0238,63512,2606,785
31 Mar 2356,7417,53512,2016,661
31 Dec 2258,05411,78212,0846,487
30 Sep 2257,81913,34312,1166,518
30 Jun 2257,34912,56911,9886,551
31 Mar 2256,72512,40711,9436,692
31 Dec 2156,19711,46811,8726,820
30 Sep 2155,1697,46511,0546,829
30 Jun 2153,7296,59910,8606,761
31 Mar 2150,1955,09210,9556,418
31 Dec 2045,8044,5569,8676,003
30 Sep 2040,6507,3249,4295,902
30 Jun 2036,2276,9068,2885,582
31 Mar 2034,0578,3956,7605,467
31 Dec 1933,2667,8426,7635,377
30 Sep 1932,8673,2326,4875,260
30 Jun 1932,6244,0936,7655,273
31 Mar 1932,6475,3336,8735,304
31 Dec 1832,7535,6577,3535,259
30 Sep 1832,1877,5316,9725,242
30 Jun 1830,9466,4196,6235,202
31 Mar 1829,6126,3526,3035,109
31 Dec 1728,2165,2836,2485,007
30 Sep 1727,2736,6155,9584,789
30 Jun 1726,7106,5825,7994,667
31 Mar 1726,2186,2785,8614,562
31 Dec 1625,6385,9235,8374,385
30 Sep 1625,2426,0485,7334,178
30 Jun 1624,7545,6905,7244,472
31 Mar 1623,7775,4485,6464,236
31 Dec 1522,8595,1185,6634,101
30 Sep 1521,9112,7906,0593,978
30 Jun 1520,9862,0646,1783,390
31 Mar 1520,4371,8026,1333,336
31 Dec 1419,9601,7656,0243,297
30 Sep 1419,6193,6865,4133,201
30 Jun 1419,2584,1445,1363,103
31 Mar 1419,0244,1145,1132,978

Quality Earnings: 4AB has a large one-off loss of $8.4B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 4AB's current net profit margins (9.1%) are lower than last year (11.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4AB's earnings have grown by 1% per year over the past 5 years.

Accelerating Growth: 4AB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4AB had negative earnings growth (-21.5%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).

Return on Equity

High ROE: Whilst 4AB's Return on Equity (84.55%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 22:45
End of Day Share Price 2024/11/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AbbVie Inc. is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Luisa HectorBerenberg